Integrated Investment Consultants LLC Purchases Shares of 4,318 AstraZeneca PLC (NASDAQ:AZN)

Integrated Investment Consultants LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,318 shares of the company’s stock, valued at approximately $336,000.

Several other hedge funds also recently modified their holdings of AZN. Cypress Capital Group acquired a new position in AstraZeneca during the third quarter valued at approximately $206,000. First Horizon Advisors Inc. boosted its holdings in shares of AstraZeneca by 27.6% in the 3rd quarter. First Horizon Advisors Inc. now owns 5,458 shares of the company’s stock valued at $425,000 after buying an additional 1,180 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of AstraZeneca by 39.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 17,810 shares of the company’s stock valued at $1,388,000 after buying an additional 5,022 shares in the last quarter. Hilton Capital Management LLC increased its holdings in AstraZeneca by 2.3% during the third quarter. Hilton Capital Management LLC now owns 175,492 shares of the company’s stock worth $13,673,000 after buying an additional 3,921 shares during the last quarter. Finally, Commerce Bank raised its position in AstraZeneca by 6.2% during the third quarter. Commerce Bank now owns 19,413 shares of the company’s stock worth $1,512,000 after acquiring an additional 1,131 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

NASDAQ:AZN opened at $65.63 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The stock has a 50 day simple moving average of $73.44 and a 200 day simple moving average of $77.79. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The stock has a market cap of $203.49 billion, a P/E ratio of 31.40, a PEG ratio of 1.18 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the previous year, the business posted $0.87 earnings per share. AstraZeneca’s quarterly revenue was up 18.0% on a year-over-year basis. Research analysts anticipate that AstraZeneca PLC will post 4.1 earnings per share for the current year.

Wall Street Analyst Weigh In

AZN has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday. Finally, TD Cowen lifted their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.